The former suggests that these cells are derived from bone marrow precursor cells, whereas the latter suggests that reduced apoptosis may result in increased cell quantity, eventually leading to cancer.[4] STAT6 immunohistochemistry reportedly has extremely high sensitivity and specificity for the presence of the NAB2–STAT6 gene fusion product, making STAT6 an excellent immunohistochemical marker for validating the diagnosis of an SFT.[18] Thus, we used immunohistochemistry to get a definitive diagnosis. The gene discussed is NAB2; the disease is cancer.